Tumor Necrosis Factor Alpha Overexpression Induces Mainly Osteoclastogenesis at the Vertebral Site.

about

Tumor Necrosis Factor Alpha Overexpression Induces Mainly Osteoclastogenesis at the Vertebral Site.

Item

http://www.wikidata.org/entity/Q47830081

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Tumor Necrosis Factor Alpha Ov ...... genesis at the Vertebral Site.

@en

Tumor Necrosis Factor Alpha Ov ...... genesis at the Vertebral Site.

@nl

type

Item

label

Tumor Necrosis Factor Alpha Ov ...... genesis at the Vertebral Site.

@en

Tumor Necrosis Factor Alpha Ov ...... genesis at the Vertebral Site.

@nl

prefLabel

Tumor Necrosis Factor Alpha Ov ...... genesis at the Vertebral Site.

@en

Tumor Necrosis Factor Alpha Ov ...... genesis at the Vertebral Site.

@nl

P1476

Tumor Necrosis Factor Alpha Ov ...... genesis at the Vertebral Site.

@en

P2093

Fabienne Coury

http://www.w3.org/2001/XMLSchema#string

Guillaume Courbon

http://www.w3.org/2001/XMLSchema#string

Norbert Laroche

http://www.w3.org/2001/XMLSchema#string

Sacha Flammier

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice

Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials

Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis

Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation

An extensive phenotypic characterization of the hTNFalpha transgenic mice.

A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling.

Tumor necrosis factor signaling.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis.

The TNF-alpha transgenic mouse model of inflammatory arthritis.

P2888

s00223-017-0237-8

P304

575-584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00223-017-0237-8

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Hubert Marotte

Laurence Vico

P577

2017-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28289800

http://www.w3.org/2001/XMLSchema#string

P921

overexpression